Olmetec Plus (olmesartan + hydrochlortiazid)
Olmetic Plus is the former licensed angiotensin-II antagonist (olmesartan) in combination with hydrochlorthiazide (HCTZ). Olmetec Plus is licensed for essential hypertension in patients with insufficient treatment of monotherapy. Dizziness is the most frequent adverse effect.
Curently Olmetec Plus is the least costly combination product of angiotensin-II antagonist/HCTZ, but yet the price is still about 5 times higher than treatment with ACE-inhibitors and thiazide.
In Denmark Olmetec Plus was marketed May 2006. Olmetec is previously reviewed by IRF (in Danish only).
Institute for Rational Pharmacotherapy, 16 May 2006